Barclays lowered the firm’s price target on Cellectis (CLLS) to $5 from $7 and keeps an Overweight rating on the shares following the Q3 report.
Barclays lowered the firm’s price target on Cellectis (CLLS) to $5 from $7 and keeps an Overweight rating on the shares following the Q3 report.